肿瘤重新发作停顿，比方肿瘤变大、扩散或转移等;

据印度代购了解，假如耐药该怎样办呢?

据印度代购了解，首先剖析到底是什么新突变招致耐药，由于每个病人对易瑞沙产生抗药性的缘由不尽相同，因而后续治疗计划也截然不同。关于易瑞沙耐药的患者中，超越一半是由于EGFR基因又产生了一个新的突变：T790M，就是EGFR蛋白的第790氨基酸由T变成了M，这个突变直接招致第一代药物无法抑止这个突变蛋白的功用，因而失效了。

According to Daigou India, the first step is to analyze exactly what new mutations lead to drug resistance, as each patient develops resistance to iressa for different reasons, so the follow-up treatment plan is very different. More than half of the patients with iressa resistance were due to a new mutation in the EGFR gene: T790M, where the 790th amino acid of the EGFR protein changes from T to M. This mutation directly caused the first generation of drugs to fail to block the function of the mutant protein and therefore failed.

据印度代购了解，针对这个突变我们有一个十分好的选择就是第三代EGFR靶向药物，阿斯利康消费的泰瑞沙。这个药上市前其实就被很多患者熟知，当时还没有名字，只要个代号叫AZD9291。

据印度代购了解，它对携带T790M突变的耐药患者效果十分好，临床实验中呈现了惊人的90%的肿瘤控制率，60%的肿瘤显著减少率，同时它入脑才能更强，因而患者假如有脑转移，这药效果也显著比以前的好。

According to The understanding of India daigu, it is very good for drug-resistant patients carrying T790M mutation, clinical trials showed an amazing 90% tumor control rate, 60% of the tumor significantly reduced rate, at the same time, it can enter the brain is stronger, so if patients have brain metastasis, the drug effect is significantly better than before.